Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cyclosporine

FDA-approved product (injectable, injection), marketed as Cequa, Cyclosporine, Gengraf and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cyclosporine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conjunctivitis
  • Corneal disease
  • Eye disease
  • Immune system disease
  • Inflammation
  • Keratitis
  • Keratoconjunctivitis
  • Psoriasis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcineurin inhibitors; Other ophthalmologicals
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cyclosporine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cyclosporine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Genetic Predictors of Renal Dysfunction Following Heart Transplantation

    NCT01686191 · start 2012-08

    Registered record
    Registry ID
    NCT01686191
    Conditions
    Heart Transplantation; Chronic Renal Insufficiency
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-08
    Completion
    2025-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplantation; Chronic Renal Insufficiency
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

    NCT01433978 · start 2012-03-26

    Registered record
    Registry ID
    NCT01433978
    Conditions
    Idiopathic Thrombocytopenic Purpura
    Interventions
    Eltrombopag; Avatrombopag; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-03-26
    Completion
    2013-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Thrombocytopenic Purpura
    InterventionEltrombopag; Avatrombopag; Standard of care
    PhasePhase 3
    Registry statusTerminated

  • Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy

    NCT02176733 · start 2011-07

    Registered record
    Registry ID
    NCT02176733
    Conditions
    Leber Hereditary Optic Neuropathy
    Interventions
    cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-07
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeber Hereditary Optic Neuropathy
    Interventioncyclosporine
    PhasePhase 2
    Registry statusUnknown

  • Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia

    NCT01997372 · start 2010-12

    Registered record
    Registry ID
    NCT01997372
    Conditions
    Severe Aplastic Anemia
    Interventions
    ATG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2015-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Aplastic Anemia
    InterventionATG
    PhasePhase 4
    Registry statusUnknown

  • Ciclosporin in the Management of New Type 1 Reactions in Leprosy

    NCT00919815 · start 2010-08

    Registered record
    Registry ID
    NCT00919815
    Conditions
    Leprosy
    Interventions
    Ciclosporin; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2013-07
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeprosy
    InterventionCiclosporin; Prednisolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

    NCT01120132 · start 2010-05

    Registered record
    Registry ID
    NCT01120132
    Conditions
    Allergic Conjunctivitis
    Interventions
    CsA high dose; CsA low dose; PA; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2010-08
    Enrolment
    716

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionCsA high dose; CsA low dose; PA; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

    NCT00938860 · start 2009-09

    Registered record
    Registry ID
    NCT00938860
    Conditions
    Hepatitis C; Liver Transplantation
    Interventions
    cyclosporin (Neoral); tacrolimus (Prograf)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-05
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Liver Transplantation
    Interventioncyclosporin (Neoral); tacrolimus (Prograf)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

    NCT00884585 · start 2009-05

    Registered record
    Registry ID
    NCT00884585
    Conditions
    Atopic Conjunctivitis
    Interventions
    Cyclosporine Vehicle; Cyclosporine 0.010%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-07
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Conjunctivitis
    InterventionCyclosporine Vehicle; Cyclosporine 0.010%
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

    NCT00840827 · start 2008-12

    Registered record
    Registry ID
    NCT00840827
    Conditions
    Myelodysplastic Syndrome
    Interventions
    lenalidomide; cyclosporine A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-12
    Completion
    2010-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndrome
    Interventionlenalidomide; cyclosporine A
    PhasePhase 2
    Registry statusTerminated

  • Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia

    NCT01530555 · start 2008-04

    Registered record
    Registry ID
    NCT01530555
    Conditions
    Acquired Aplastic Anaemia
    Interventions
    Rabbit ATG, Thymoglobuline (Genzyme)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-04
    Completion
    2013-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Aplastic Anaemia
    InterventionRabbit ATG, Thymoglobuline (Genzyme)
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

    NCT00634920 · start 2008-03

    Registered record
    Registry ID
    NCT00634920
    Conditions
    Renal Function
    Interventions
    everolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids; Basiliximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-05
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Function
    Interventioneverolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids +1 more
    PhasePhase 4
    Registry statusCompleted

  • PsoBest - The German Psoriasis Registry

    NCT01848028 · start 2008-01

    Registered record
    Registry ID
    NCT01848028
    Conditions
    Psoriasis; Psoriatic-arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-01
    Completion
    2032-12
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Psoriatic-arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Oasys vs. Extreme H20 Xtra 59

    NCT00477763 · start 2007-05

    Registered record
    Registry ID
    NCT00477763
    Conditions
    Dry Eye
    Interventions
    Restasis, Refresh Endura
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2008-02
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionRestasis, Refresh Endura
    PhasePhase 4
    Registry statusCompleted

  • Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient

    NCT00452361 · start 2007-04

    Registered record
    Registry ID
    NCT00452361
    Conditions
    Kidney Transplantation
    Interventions
    Sirolimus+MMF or MPS or AZA+Steroid; Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-04
    Completion
    2008-08
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation
    InterventionSirolimus+MMF or MPS or AZA+Steroid; Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
    PhasePhase 4
    Registry statusTerminated

  • Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome

    NCT00378677 · start 2007-02

    Registered record
    Registry ID
    NCT00378677
    Conditions
    Lung Transplantation; Bronchiolitis Obliterans
    Interventions
    Cyclosporine A dry powder inhalation (Drug)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2007-02
    Completion
    Not recorded
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Transplantation; Bronchiolitis Obliterans
    InterventionCyclosporine A dry powder inhalation (Drug)
    PhaseEarly phase 1
    Registry statusUnknown